Sublingual Immunotherapy for Allergic rhinitis
Article Sidebar
Main Article Content
Abstract
Allergic rhinitis is found in 20 percent of Thai patients. They present with symptom of chronic rhinitis with or without complications such as sinusitis, asthma and snoring. The treatments are avoidance of allergens, pharmacotherapy and immunotherapy. The allergens commonly found in Thailand are divided into indoor pollen, such as house-dust mites, house dust, cock-roaches, dogs and cat’s hair and outdoor allergens such as pollen, Bermuda grass, para grass, sedge, careless weed. We use immunotherapy to treat the underlying cause of the disease. By allergen injected under the skin. Or sublingually, to make our body reduces the allergic response to allergens. By immunotherapy, we can change natural course of the disease and keep therapeutic effects after stopping the drug.
Sublingual immunotherapy (SLIT) showed effective in the treatment of allergic rhinitis in the long term find therapeutic for both nasal and eye symptom and found to reduce drug use significantly. These results suggest that the efficacy of SLIT treatments begin in 14th week, that symptoms are reduced significantly.
The study found that was not any serious complications. SLIT with avoid allergens (Avoidance) are proper for treatment of allergic rhinitis. To avoid complication of treatment should be considered in patients with a clear indication and no contraindications to treatment.
Article Details
References
Bunnag C, Jareoncharsri P, Tantilipikorn P Epidemiology and Current Status of Allergic Rhinitis and Asthma in Thailand- ARIA Asia-Pacific Workshop Report, Asean Pac J Allergy Immunol 2009; 27: 79-86.
Ullrich D, Thum-Oltmer S Successful specific subcutaneous immunotherapy (SCIT) with non-modified semi-depot pollen and mite preparations Results of a post-marketing surveillance study. Allergo J 2007; 16: 193–8.
Bousquet J, Lockey RF and Malling HJ.WHO Vajira Medical Journal: Journal of Urban Medicine
Nelson, H.S: diagnostig procedures in allergy, I. Allergic skin testing, Annals allergy 1983; 51: 411-18.
King HC End point titration and immunotherapy, Otol Clin N Am 1985; 18: 703-17.
Noon L. Prophylactic inoculation for Hay fever. Lancet 1911; 1: 1572.
Cooke L. The treatment of Hay fever by active immunization. Laryngol 1915; 25:108.
Rinkel HJ. The management of clinical allergy (I, II, III), Arch Otolaryngol 1962; 76: 469-508, 1963; 77: 42-75, and 1963; 77: 205-25.
Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis Clin Exp Allergy 2011; 41(9):1263-72.
Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-72.
Abramson M, Puy R and Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54: 1022-41.
Walker SM, Pajno GB, Torres-Lima M, Wilson DR and Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial J allergy Clin Immunol 2001; 107: 87-93.
Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF Jr, Buncher CR, et al. Ragweed immunotherapy in adult asthma. N England J Med 1996; 334(8): 501-6.
Holger M, Walter C, Vibeke B, Frederic de B, Ludger K, Louise B. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms Ann Allergy Asthma Immunol 2015; 114: 134-40.
Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy 2017; 72: 435–43.
Matthew AR, JAMES TCLI. Allergen Immunotherapy. Mayo Clin Proc. 2007; 82(9): 1119-23.
Roberts, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018; 73: 765–98.
Mubeccel A, Cezmi AA. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens J Allergy Clin Immunol 2014; 133: 621-31.
Natasha CG, Stephen RD. New approaches to allergen immunotherapy Ann Allergy Asthma Immunol 2018; 121: 293-305.
Martin JB, John HK, Richard MR. Extracts from The Cochrane Library: Allergen injection immunotherapy for seasonal allergic rhinitis (review) Otolaryngol Head Neck Surg 2007; 136: 511-4.
Pascal D, Waltraud E, Dorte R, Vibeke B, Lene T, Jorg KT. Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 2016; 137: 444-51.
Linda C. Sublingual immunotherapy for aeroallergens: Status in the United States. Allergy Asthma Proc 2014; 35: 34–42.
Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al. Long-term clinical efficacy of grass pollen immunotherapy. New Eng J Med 1999; 341: 468-75.
Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP and Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinnus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Chin Immunol 1997; 99 (4): 450-53.
Pajno GB, Barberio G, De Luca F, Morabito L and Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: A six-year follow-up study. Clin Exp Allergy 2001; 31(9): 1392-7.
Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109: 251-6.
Committee on safety of Medicines. Desensitisation vaccines. BMJ 1996; 293: 949.
Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitz berg D, et al, Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016; 138(6): 1631-8.
Glieich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982; 70(4): 261-71.
Lichtenstive LM, Holtzman NA, Burnett LS. A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol. 1968; 101(2): 317-24.
Gafvelin G, Thunberg S, Kronqvist M,Gronlund H, Gronneberg R, Troye-Blomberg M, et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005; 138: 59-66.
Passalacqua G, Durham SR. Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. J Allergy Clin Immunol. 2007; 119: 881-91.
Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoidss. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988; 82 (3 pt1): 439-46.
Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Allergy Clin Immunol. 2006; 116: 883-41.
Zhu D, Kepley CL, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med. 2002;8: 518-21.
Till SJ, Fracis JN, Nouri-Aria K and Durham SR. Mechanisms of immunotherapy. Review. J Allergy Clin Immun ol. 2004; 113 (6): 1025-34.
Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003; 111: 1255-61.
Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-14.
Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004; 172: 3252-9.
Majori M, Bertacco S, Picoli ML, Melej R, Pileggi V, Pesci A. Specific immunotherapy downregulates peripheral blood CD4 and CD8 T-lymphocytes activation in glass pollen-sensitive asthma. Eur Respir J. 1998; 11(6): 1263-7.
Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb al-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol. 2004; 113: 235-41.
Bousquet J, Becker WM, Hejjaoui A, Channal I, Lebel B, Dhivert H, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol. 1991; 88(1): 43-53.
Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackey IS, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996; 97(6): 1356-65.
Hedlin G, Silber G, Naclerio R, Proud D, Lamas AM, Eggleston P, et al. Comparison of the in-vivo and in-vitro response to ragweed immunotherapy in children and adults with ragweed-induced rhinitis. Clin Exp Allergy. 1990; 20(5): 491-500.
Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB. Shor-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy. 1999; 29(10): 1326-35.
Durham SR, Varney VA, Gaga M, Jacobson MR, Varga EM, Frew AJ, et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy. 1999; 29: 1490-6.
Wilson DR, Nouri-Aria KT, Walker SM, Panjno GB, O’Brien F, Jaconson MR, et al. Grass pollen immunotherapy: symptomatic improvement correlated with reductions in eosiphils and IL-5mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol. 2001; 107: 971-6.
Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double-blind placebo-controlled study. Allergy. 2004; 59: 74-80
Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003; 111: 1255-61.
Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003; 33: 1205-14.
Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004; 172: 3252-9.
Cappella A, Durham SR. Human Vaccines & Immunotherapeutics. 2012; 8(10): 1499-1512.